{"id":"NCT00631969","sponsor":"Bayer","briefTitle":"Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction","officialTitle":"Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial - POTENT I","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2008-03-10","resultsPosted":"2011-01-21","lastUpdate":"2014-12-30"},"enrollment":362,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Erectile Dysfunction"],"interventions":[{"type":"DRUG","name":"Vardenafil ODT (STAXYN, BAY38-9456)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vardenafil ODT (STAXYN, BAY38-9456)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.","primaryOutcome":{"measure":"Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or LOCF","timeFrame":"from baseline up to 12 weeks","effectByArm":[{"arm":"Vardenafil ODT (STAXYN, BAY38-9456)","deltaMin":9.6,"sd":6.28},{"arm":"Placebo","deltaMin":2.1,"sd":7.33}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":47,"countries":["Belgium","France","Germany","Netherlands","South Africa","Spain"]},"refs":{"pmids":["21883954","20233275","20925442","20807322"],"seeAlso":["http://www.clinicaltrialsregister.eu"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":184},"commonTop":["Headache","Flushing","Dysgeusia","Dyspepsia","Supraventricular extrasystoles"]}}